AFP and hepatocellular carcinoma: Additionally, combining IL-13/STAT6 with serum AFP also increased predictive power of serum AFP and increased its specificity, sensitivity, and accuracy for predicting HCC development in high fibrosis grades F3 and F4 NASH patients.